Obinutuzumab drives histologic remission in lupus nephritis At #EULAR2026, new data from the phase III REGENCY trial add to the case for obinutuzumab in lupus nephritis. Investigators report deep intrarenal B-cell depletion and significantly higher rates of histological https://t.co/AlJ5I8s2JE

RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/FXCKlyKYfr

Join Dr. Jack Cush and Dr. Arthur Kavanaugh live for the EULAR 2026 Rheumatology Round-Up on Friday, June 12 at 1:00 PM ET as they break down the meeting's biggest stories, practice-changing data, and key clinical takeaways. From late-breaking research and emerging therapies to https://t.co/Tl9U6F14OM

Immune Dimming or Immune Reset in RA: How Far Should We Go? CD19 CAR T-cell therapy has moved from oncology to autoimmune disease after SLE reports of sustained drug-free remission suggesting an immune reset. This raises whether profound depletion is needed or if milder https://t.co/WONQmhs86j

New: Classification Criteria and Recommendations in SpA ASAS and SPARTAN have updated their key classification criteria for axSpA. EULAR has also recently revised its recommendations on the role of imaging in the diagnosis and clinical management of SpA. https://t.co/YOWfwTkbqp

Improving Referrals for Inflammatory Arthritis Dr. Antoni Chan discusses abstracts POS1284 and POS0784 presented at EULAR 2026 in London https://t.co/p1iT8yPNzF https://t.co/gEyuEwW4aj

Gout and ULT Withdrawal -- The GO TEST FINALE Trial Professor Noortje van Herwaarden reviews abstract OP001 at EULAR 2026 in London https://t.co/d8U1168SRn https://t.co/hP0EUrciTu

Day 3 Recap: EULAR 2026 Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288 https://t.co/TSnVVOpF75 https://t.co/EFD0WKRpF4

Exploring Idiopathic Myopathies #EULAR2026: Idiopathic inflammatory myopathies (IIM) are a diverse group of autoimmune diseases with significant morbidity. While EULAR/ACR classification criteria were established in 2017, updated real-world data and better tools to assess https://t.co/CbUWodWT7z

What’s New in Psoriatic Arthritis: A Whirlwind Tour At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/IzsSzx6Pc9

Strike First: TNFi vs. Step-Up Therapy in Early Peripheral SpA The approach to treating peripheral SpA has remained the same for a long time. The guidelines recommend starting with NSAIDs, escalating to conventional synthetic DMARDs, typically sulfasalazine or methotrexate, and https://t.co/iEqzp6FStv